You are here

Article Text

Article menu
Download PDFPDF
Miscellaneous
Letter
Response to Berlaimont and Welby
  1. Marta Checchi,
  2. David Mesher,
  3. Hamish Mohammed,
  4. Kate Soldan
  1. Blood Safety, Hepatitis, Sexually Transmitted Infections (STI) and HIV Service, Public Health England, London, UK
  1. Correspondence to Ms Marta Checchi, Blood Safety, Hepatitis, Sexually Transmitted Infections (STI) and HIV Service, Public Health England, London NW9 5EQ, UK; marta.checchi{at}phe.gov.uk

https://doi.org/10.1136/sextrans-2019-054148

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Berlaimont and Welby have queried why our recent publication (Checchi et al )1 reporting the declining trend in genital warts (GW) diagnoses in young people attending specialist sexual health services in England does not consider cross-protection of the bivalent human papillomavirus (HPV) vaccine against GW as a contributing explanation.

    In a previous analysis of data to 2014 (Canvin et al), we concluded that the observed trends in young people from 2009 to 2014 were strongly in keeping with a modest cross-protective effect, and associated herd-protection, from the bivalent vaccine.2 Since then, evidence has not amassed to support that hypothesis. Most notably, data from our surveillance of …

    View Full Text

    Footnotes

    • Handling editor Anna Maria Geretti

    • Contributors This letter was initiated and drafted by MC, DM and KS. HM was responsible for the source data included in the original analysis. All authors contributed to and approved the final draft of the letter.

    • Competing interests None declared.

    • Patient consent for publication Not required.

    • Provenance and peer review Not commissioned; internally peer reviewed.